Richard Aplenc

Trials

Studies that name Richard Aplenc as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:54 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT03971799 · Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

  Center for International Blood and Marrow Transplant Research · active not recruiting · Acute Myelogenous Leukemia · principal investigator
• N/A
  NCT02794207 · Home or Away From Home - Descriptive Interviews (Aim 2)

  Children's Hospital of Philadelphia · completed · Pediatric Acute Myeloid Leukemia · principal investigator
• N/A
  NCT02777021 · Home Away From Home - Quality of Life Surveys

  Children's Hospital of Philadelphia · completed · Pediatric Acute Myeloid Leukemia · principal investigator
• N/A
  NCT02774850 · Home Away From Home - Medical Outcomes

  Children's Hospital of Philadelphia · completed · Acute Myeloid Leukemia, Neutropenia, Bacteremia · principal investigator
• Ph3
  NCT01371981 · Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  National Cancer Institute (NCI) · completed · Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm · principal investigator
• N/A
  NCT01024127 · Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

  Children's Oncology Group · completed · Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission · principal investigator
• Ph1
  NCT00933985 · Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

  National Cancer Institute (NCI) · terminated · Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma · principal investigator
• N/A
  NCT00897507 · DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia

  Children's Oncology Group · completed · Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia · principal investigator
• Ph3
  NCT00372593 · Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

  Children's Oncology Group · completed · Leukemia · study chair
• Ph1
  NCT00316953 · Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

  National Cancer Institute (NCI) · completed · Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia · principal investigator
• Ph1
  NCT00028899 · Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

  Children's Oncology Group · completed · Leukemia, Myelodysplastic Syndromes · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Database Harmonization for Creation and Validation of Outcome Assessments and Prediction Tools for Metachromatic Leukodystrophy (MLD)
  R61NS135584 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2025 to 2026 · $860,671 awarded in 2026
  Same name and institution; not confirmed by an ID
• Predicting and Monitoring for Cardiac Toxicity in Pediatric AML
  R01HL163657 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2023 to 2026 · $459,360 awarded in 2026
  Same name and institution; not confirmed by an ID
• PROMISE — Pediatric Rare-tumor Observational MultI-Source Evidence Network
  U01FD008977 · FDA · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $1,498,821 awarded in 2026
  Same name and institution; not confirmed by an ID
• COG NCTN Network Group Operations Center
  U10CA180886 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2020 · $2,702,029 awarded in 2020
  Grant number is on one of their registry trials
• Toxicity Monitoring on Phase III Trials with Administrative Data
  R01CA165277 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2012 to 2015 · $410,314 awarded in 2015
  Same name and institution; not confirmed by an ID
• Genetic Predictors of AML Treatment Response
  R01CA133881 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2010 to 2014 · $455,264 awarded in 2014
  Same name and institution; not confirmed by an ID
• GENETIC PREDICTORS OF LEUKEMIA THERAPY RESPONSE
  R01CA108862 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2005 to 2009 · $256,197 awarded in 2009
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Children's Oncology Group Chair's Grant
  U10CA098543 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI PETER C. ADAMSON · fiscal years 2003 to 2013
  Named on NCT01371981, NCT00897507
• Children's Oncology Group Phase 1 / Pilot Consortium
  U01CA097452 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI SUSAN M. BLANEY · fiscal years 2002 to 2011
  Named on NCT00933985